ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.695
      -0.11%
      Bitcoin
      64,749.50
      -0.60%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Sanofi (SAN)

      7. Sanofi (SAN) News

      SAN

      Sanofi (SAN)

      Sanofi
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:SAN
      DateTimeSourceHeadlineSymbolCompany
      06/12/20242:19PMGlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares – May 2024EU:SANSanofi
      06/12/20242:19PMGlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024EU:SANSanofi
      06/03/20244:15PMGlobeNewswire Inc.Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]EU:SANSanofi
      06/03/20244:15PMGlobeNewswire Inc.Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3EU:SANSanofi
      06/03/20244:15PMGlobeNewswire Inc.Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3EU:SANSanofi
      05/31/20246:00AMGlobeNewswire Inc.Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salariéEU:SANSanofi
      05/31/20246:00AMGlobeNewswire Inc.Press Release: Sanofi launches 2024 global Employee Stock Purchase PlanEU:SANSanofi
      05/31/20246:00AMGlobeNewswire Inc.Press Release: Sanofi launches 2024 global Employee Stock Purchase PlanEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
      05/31/20241:00AMGlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2EU:SANSanofi
      05/31/20241:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
      05/31/20241:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
      05/30/20249:01AMGlobeNewswire Inc.Press Release: Sanofi completes acquisition of Inhibrx, Inc.EU:SANSanofi
      05/30/20249:01AMGlobeNewswire Inc.Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc.EU:SANSanofi
      05/30/20249:01AMGlobeNewswire Inc.Press Release: Sanofi completes acquisition of Inhibrx, Inc.EU:SANSanofi
      05/27/20241:00AMGlobeNewswire Inc.Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myelomaEU:SANSanofi
      05/27/20241:00AMGlobeNewswire Inc.Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantationEU:SANSanofi
      05/27/20241:00AMGlobeNewswire Inc.Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myelomaEU:SANSanofi
      05/21/20241:30AMGlobeNewswire Inc.Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationEU:SANSanofi
      05/21/20241:30AMGlobeNewswire Inc.Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationEU:SANSanofi
      05/21/20241:30AMGlobeNewswire Inc.Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IAEU:SANSanofi
      05/20/20244:54PMGlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024EU:SANSanofi
      05/20/20244:54PMGlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - April 2024EU:SANSanofi
      05/20/20242:15PMGlobeNewswire Inc.Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCOEU:SANSanofi
      05/20/20242:15PMGlobeNewswire Inc.Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMEU:SANSanofi
      05/20/20242:15PMGlobeNewswire Inc.Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMEU:SANSanofi
      05/13/20241:00AMGlobeNewswire Inc.Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereigntyEU:SANSanofi
       Showing the most relevant articles for your search:EU:SAN